US drugmaker Pfizer is becoming more confident about the current year. With a good run, the group raised the bottom line growth forecast when delivering the third-quarter numbers and also raised its adjusted earnings per share forecast.
Third-quarter results showed commercial strength in many areas of the business, but it was somewhat overshadowed by the strong performance last year, Chief Financial Officer David Denton said Tuesday in New York. Also, Pfizer is facing some headwinds from the strong dollar. Overall, the group performed better than expected by analysts.
“Total coffee aficionado. Travel buff. Music ninja. Bacon nerd. Beeraholic.”
More Stories
Wealthy families take more risks when it comes to money.
Salesforce and NVIDIA Form Strategic Collaboration to Drive AI Customer Innovation
Changing banks causes problems for customers